Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- Jul 16, 2020- Worldwide sales of $7.3 billion in the second quarter, including $615 million of COVID-19 diagnostic testing-related sales- Growth rates in business areas initially most impacted by COVID-19 improved significantly over the course of the second quarter- Abbott continues to strengthen its portfolio with several recent regulatory approvals, including FreeStyle Libre 2, TriClip and Gallant heart devices
- Apr 16, 2020- First-quarter sales growth of 2.5 percent; organic sales growth of 4.3 percent- Recently launched three breakthrough diagnostics tests for coronavirus (COVID-19)
- Jan 22, 2020- Fourth-quarter sales growth of 7.1 percent; organic sales growth of 8.5 percent- Fourth-quarter GAAP EPS growth from continuing operations of 59.5 percent and adjusted EPS growth from continuing operations of 17.3 percent- Several businesses achieved double-digit sales growth- Forecast reflects continued top-tier sales and earnings growth for 2020